Procalcitonin
[Procalcitonin]
EPTIS Ringversuch Nr. 1177224 | Letze Änderung 2024-09-24 | URL: https://www.eptis.bam.de/pts1177224 https://www.eptis.bam.de/pts1177224
| Name des Anbieters | |||||||
| Name des Anbieters | Weqas Weqas | ||||||
| Ansässig in | United Kingdom | ||||||
| Sprache(n) | |||||||
| Anmerkungen | Procalcitonin (PCT) has developed into a promising biomarker for identifying serious bacterial infections, to distinguish between bacterial and non-bacterial conditions and to guide antibiotic treatment. The diagnostic accuracy of procalcitonin in detecting infection was found to be useful for early diagnosis of sepsis and subsequent reduction of mortality in critically ill patients. Three liquid human serum samples are distributed monthly, with a minimum of 36 samples distributed over the year covering a wide clinically relevant range. The samples consist of a panel of 6 linearly related samples produced from donations from healthy volunteers spiked with a highly purified source of recombinant PCT to provide an extended clinical range. The programme assesses both laboratory and method performance, including bias, within and between batch imprecision and linearity. Key Features: - Samples provided to cover range of Procalcitonin concentrations seen in both LRTI and systemic bacterial infection or severe sepsis. - Samples suitable for Laboratory and POCT applications. - Panel of linearly related samples produced from donations from healthy volunteers spiked with procalcitonin. - The linearly related samples are distributed on a number of occasions over the year to assess both laboratory and method performance, including linearity, bias, within and between batch imprecision. For more information: https://www.weqas.com/services/eqa/procalcitonin/ or contact@weqas.com | ||||||
| Klassifizierung | |||||||
| Produktgruppen |
Health care / medical devices
|
||||||
| Prüfgebiete |
Medical analysis
|
||||||
| Technische Einzelheiten | |||||||
|
|||||||
| Ringversuchsziele | |||||||
| Zielgruppe des Ringversuchs | Samples suitable for Laboratory and POCT applications. | ||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS based on ISO/IEC 17043. | ||||||
| Weitere Ziele | validation of testing methods and also Quality and comparability of reporting | ||||||
| Teilnehmerzahl | |||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 nicht für alle Parameter |
||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | |||||||
| Kosten | |||||||
| Teilnahmegebühr | https://www.weqas.com/participantzone/subscription-charges/ | ||||||
| Regelmässig durchgeführt | Ja (Frequency: Monthly. Samples: 3 x 0.5mL. ) | ||||||
| Der Ringversuch wird durchgeführt seit | 2019 | ||||||
| Kontaktdaten des Anbieters | |||||||
| Anbieter | Kontaktperson | ||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.